Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 2;138(14):1258–1268. doi: 10.1182/blood.2020010331

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 4. — Activity of Mim8 in HA plasma and whole blood. (A-B) Peak thrombin generation (mean ± standard deviation, n = 5-8) in FXIa-triggered (1 mU/mL) platelet-poor severe congenital HA plasma supplemented with FVIII (A) or Mim8, emicizumab SIA, or Mim8 in combination with 100 U/dL FVIII (B). Using a variable slope 4-parameter model, 50% effective concentration of 12 ± 2 nM (Mim8) and 153 ± 29 nM (emicizumab SIA) were estimated. (C) Peak thrombin generation of Mim8 or emicizumab SIA in platelet-rich plasma (250 000-320 000 platelets/µL) from healthy volunteers supplemented with neutralizing anti-FVIII polyclonal antibody and triggered with 1 pM TF. (D) Effect of Mim8 or emicizumab SIA on the time to clot (R-time; mean ± standard deviation, n = 6) in whole blood from healthy volunteers supplemented with neutralizing anti-FVIII polyclonal antibody. Clot formation was triggered with TF (∼30 fM) and monitored by using thromboelastography (TEG). Using the same model as in panels A and B, 50% effective concentrations of 0.18 ± 0.02 nM (Mim8) and 6.2 ± 0.9 nM (emicizumab SIA) were estimated. Ranges obtained under normal or HA conditions are highlighted in light blue.